A new approach to refractory gastrointestinal stromal tumours with diverse acquired mutations

Molecular targeted therapy has improved the prognosis for patients with advanced cancers with driver mutations as seen in lung adenocarcinomas, leukaemia, and gastrointestinal stromal tumours. Targeted agents include antibodies or small molecules that specifically bind to proteins coded by driver alterations. The clinical efficacy of these drugs, however, can be limited by the emergence of refractory clones with resistant mutations. These...